Health Care and Biotech

HeartWare is developing a device for treating heart failure and Southern Cross Equities rates the stock as a Speculative Buy.

Quarterly earnings for ResMed were better than many in the market had expected, leading to increases to forecasts and continued positive views on the stock.

RBS Morgans remains positive on the outlook for shares in biotech Acrux.

The strong Aussie is wiping about 9% off CSL’s earnings but can the Octa recall make up for the difference?

Competitor Octapharma has been temporarily taken out of the European and US IVIG markets and while this could tighten the global market brokers see few lasting earnings benefits for CSL.

Southern Cross Equities has initiated coverage on QRxPharma with a Speculative Buy rating, seeing the group’s MoxDuo drug as a potential company maker.

Morgan Stanley suggests Diversified Resources stocks are about to enjoy upgrades to market forecasts. Plus a rally for copper. Plus the latest views on media stocks in Australia.

Medical device technology group ImpediMed has signed a contract with a US managed care organisation and RBS Morgans expects more deals will follow, with positive implications for the share price.

Primary Health Care delivered a disappointing full year earnings result and despite cutting forecasts brokers continue to see earnings risk to the downside in FY11.

Phosphagenics is trying to develop an anti-fat drug delivered via the skin, which if successful would offer significant upside according to Southern Cross Equities.